Minimal PD-1 expression in mouse and human NK cells under diverse conditions.
暂无分享,去创建一个
D. Longo | J. Serody | S. Anderson | W. Murphy | B. Blazar | Kevin M. Stoffel | R. Canter | M. Darrow | A. Monjazeb | J. V. van Dyke | Lam T. Khuat | C. Dunai | Ethan G. Aguilar | Sarah C. Vick | S. Judge | Ian R. Sturgill | J. V. Van Dyke
[1] Bin Zhang,et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. , 2019, The Journal of clinical investigation.
[2] R. Negrin,et al. Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. , 2019, JCI insight.
[3] A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer , 2019, Case Medical Research.
[4] R. Herbst,et al. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis , 2019, Clinical Cancer Research.
[5] É. Vivier,et al. Targeting natural killer cells in solid tumors , 2019, Cellular & Molecular Immunology.
[6] K. Qu,et al. Liver‐Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD‐1‐PD‐L1 Axis , 2019, Immunity.
[7] Qiao Li,et al. Abstract A014: Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy , 2019, Clinical Trials of Cancer Immunotherapies.
[8] N. Tumino,et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression , 2018, Oncoimmunology.
[9] M. Caligiuri,et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. , 2019, Cancer discovery.
[10] S. Vesely,et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade , 2018, Nature Medicine.
[11] M. McBurney,et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.
[12] É. Vivier,et al. Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells , 2018, Nature Immunology.
[13] Huan Wang,et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.
[14] S. Endres,et al. Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies , 2018, Scientific Reports.
[15] J. Tolar,et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. , 2018, JCI insight.
[16] C. Crane,et al. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells , 2018, Front. Immunol..
[17] A. Kamphorst,et al. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. , 2018, Annual review of medicine.
[18] Jeffrey S. Miller,et al. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells , 2018, Cancer Immunology, Immunotherapy.
[19] J. Modiano,et al. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial , 2017, Journal of Immunotherapy for Cancer.
[20] K. Rezvani,et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.
[21] Y. Cheng,et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers , 2017, Oncogene.
[22] Z. Tian,et al. NK Cell Exhaustion , 2017, Front. Immunol..
[23] Jeffrey S. Miller,et al. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. , 2017, Seminars in immunology.
[24] Daniel M. Corey,et al. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.
[25] Alexander A. Tong,et al. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma , 2017, Oncoimmunology.
[26] J. Modiano,et al. Canine cancer immunotherapy studies: linking mouse and human , 2016, Journal of Immunotherapy for Cancer.
[27] Xi Chen,et al. Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway , 2016, Nature.
[28] A. Hakimi,et al. The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.
[29] D. Olive,et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma , 2016, Oncotarget.
[30] S. Sen,et al. Analysis of Ly49 gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression , 2016, Genes and Immunity.
[31] L. Lanier,et al. Natural killer cell memory in infection, inflammation and cancer , 2016, Nature Reviews Immunology.
[32] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[33] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[34] Cathrine A. Miner,et al. Acquisition of Activation Receptor Ligand by Trogocytosis Renders NK Cells Hyporesponsive , 2015, The Journal of Immunology.
[35] I. Osman,et al. Reversal of natural killer cell exhaustion by TIM-3 blockade , 2014, Oncoimmunology.
[36] Jeffrey S. Miller,et al. Clinical utility of natural killer cells in cancer therapy and transplantation. , 2014, Seminars in immunology.
[37] V. Kuchroo,et al. Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade , 2014, Cancer Immunology Research.
[38] Jeffrey S. Miller,et al. NK cells in therapy of cancer. , 2014, Critical reviews in oncogenesis.
[39] E. Plimack,et al. PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection , 2013, Cancer Immunology Research.
[40] Y. Kerdiles,et al. T cell regulation of natural killer cells , 2013, The Journal of experimental medicine.
[41] Rosanna La Rocca,et al. Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.
[42] L. Xerri,et al. PD-1 is a novel regulator of human B-cell activation. , 2013, International Immunology.
[43] F. Locatelli,et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells , 2013, Front. Immun..
[44] L. Hurton,et al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.
[45] Y. Kerdiles,et al. The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells. , 2011, International immunology.
[46] E John Wherry,et al. T cell exhaustion , 2011 .
[47] H. Karasuyama,et al. NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo , 2011, The Journal of Immunology.
[48] Dean Anthony Lee,et al. Expansion, purification, and functional assessment of human peripheral blood NK cells. , 2011, Journal of visualized experiments : JoVE.
[49] M. Caligiuri,et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.
[50] D. Campana,et al. Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors , 2010, Clinical Cancer Research.
[51] F. Locatelli,et al. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. , 2009, Clinical immunology.
[52] Yuan Zhang,et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells , 2009, Cancer Immunology, Immunotherapy.
[53] Soo‐Woong Lee,et al. Interferon-sensitive response element (ISRE) is mainly responsible for IFN-alpha-induced upregulation of programmed death-1 (PD-1) in macrophages. , 2008, Biochimica et biophysica acta.
[54] R. Peebles,et al. Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection. , 2008, Viral immunology.
[55] P. Moreau,et al. Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.
[56] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[57] T. Whiteside,et al. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use , 1994, Cancer Immunology, Immunotherapy.
[58] E. Bloemena,et al. Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment , 1994, Cancer Immunology, Immunotherapy.
[59] M. Altfeld,et al. Standardization of cytokine flow cytometry assays , 2005, BMC Immunology.
[60] L. Lanier,et al. Virus-driven evolution of natural killer cell receptors. , 2002, Microbes and infection.
[61] L. Lanier,et al. Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors , 2002, Science.
[62] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[63] R. Vance,et al. Regulation of the natural killer cell receptor repertoire. , 2001, Annual review of immunology.
[64] J. Whitton,et al. NK Markers Are Expressed on a High Percentage of Virus-Specific CD8+ and CD4+ T Cells1 , 2000, The Journal of Immunology.
[65] C. Feighery,et al. Collagenase and Dispase enzymes disrupt lymphocyte surface molecules. , 1996, Journal of immunological methods.
[66] T. Honjo,et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.
[67] M. Caligiuri,et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.
[68] J. Gong,et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. , 1994, Leukemia.
[69] R. Herberman,et al. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. , 1989, Journal of immunology.
[70] M. Bennett,et al. Mechanism of anti-asialo GM1 prevention of graft-vs-host disease: identification of allo-antigen activated T cells. , 1988, The Journal of investigative dermatology.
[71] A. Santoni,et al. Reactivity of Anti‐Asialo GM1 Serum With Tumoricidal and Non‐Tumoricidal Mouse Macrophages , 1985, Journal of leukocyte biology.